An observational retrospective study of Bevacizumab-awwb, the first FDA-approved biosimilar, assessing the real world experience in the USA
Latest Information Update: 26 Feb 2021
At a glance
- Drugs Bevacizumab (Primary)
- Indications Brain cancer; Cervical cancer; Colorectal cancer; Non-small cell lung cancer; Renal cell carcinoma
- Focus Therapeutic Use
- 26 Feb 2021 New trial record
- 17 Jan 2021 Results presented at the 2021 Gastrointestinal Cancers Symposium